Late Breaking Data from the Society for Immunotherapy of Cancer 2016
Immunotherapies have improved patient responses and survival, though not all patients benefit. Effective biomarkers may help improve outcomes. Durvalumab is a human IgG1 monoclonal antibody that inhibits programmed death ligand-1 (PD-L1) binding to programmed death-1 and B7.1/CD80, restoring antitumor immunity. PD-L1 expression on tumor or tumor-infiltrating immune cells measured manually with different immunohistochemistry (IHC) assays can enrich for patients responding to anti-PD1/PD-L1 agents. Tumor-infiltrating cytotoxic CD8+ T cells may also have potential predictive utility for therapeutic response. We explored automated image analysis and pattern recognition of tumor biopsies to determine whether CD8+ and PD-L1+ cells densities could better identify patients most likely to respond to durvalumab than PD-L1 IHC alone.
In this webinar, Dr Althammer will demonstrate:
- How Tissue Phenomics® can support you to quantify different cell populations based on multiple biomarker expression profiles (CD8(+) and PD-L1(+)) and to further investigate correlations of the density of those populations to the clinical data
- How Tissue Phenomics® has been used to detect the improved predictive value for Durvalumab treatment by combining CD8 and PD-L1 evaluation compared to PD-L1 alone
The presentation represents the team effort of groups at DEFINIENS and MedImmune and was recently presented at the SITC conference.